Privigen is a ready-to-use 10% liquid intravenous immunoglobulin
(IVIg) with no warming or reconstitution necessary. It should be
given by a separate infusion line and not mixed with other
See the chart below, or use the dosing
calculator, to find the correct dosage for your patient.
*Privigen may be diluted with Dextrose Injection, USP (D5W).
|Dose||200–800 mg/kg (2–8 mL/kg) every 3–4 weeks||1 g/kg (10 mL/kg) daily for 2 consecutive days|
|Initial infusion rate||0.5 mg/kg/min (0.005 mL/kg/min)||0.5 mg/kg/min (0.005/mL/kg/min)|
|Maximum infusion rate (if tolerated)||Increase to 8 mg/kg/min (0.08 mL/kg/min)||Increase to 4 mg/kg/min (0.04 mL/kg/min)|
|Indication||Dose||Initial infusion rate||Maximum infusion rate (if tolerated)|
|PI||200–800 mg/kg (2–8 mL/kg) every 3–4 weeks||0.5 mg/kg/min (0.005 mL/kg/min)||Increase to 8 mg/kg/min (0.08 mL/kg/min)|
|Chronic ITP||1 g/kg (10 mL/kg) daily for 2 consecutive days||0.5 mg/kg/min (0.005/mL/kg/min)||Increase to 4 mg/kg/min (0.04 mL/kg/min)|
Monitor the patient’s vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.
Increase to 4 mg/kg/min
Increase to 8 mg/kg/min
Please consult the prescribing information for complete dosing and infusion information.
To order, please contact your GPO or distributor. Privigen is available in these four convenient vial sizes:
|Fill Size (mL)||50|
|Fill Size (mL)||100|
|Fill Size (mL)||200|
|Fill Size (mL)||400|
When starting new patients on Privigen therapy:
If you are transitioning patients from another IVIg product to Privigen:
Patients receiving Privigen should be observed and monitored carefully throughout the infusion. If adverse reactions occur, the infusion should be slowed or stopped until the symptoms subside. The infusion may then be resumed at a lower rate that is comfortable for the patient. Following are some other things to keep in mind:
Privigen is contraindicated in patients with history of anaphylactic or severe systemic reaction to human immune globulin, in patients with hyperprolinemia, and in IgA-deficient patients with antibodies to IgA and history of hypersensitivity.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may be associated with the administration of Immune Globulin Intravenous (Human) (IVIg) products in predisposed patients. Administer IVIg products at the minimum dose and infusion rate possible. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIg products containing sucrose. Privigen does not contain sucrose.